B. Mennecier

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

Predictive Factors of Hospitalization for Acute Exacerbation in a Series of 64 Patients with Chronic Obstructive Pulmonary Disease

Romain Kessler, M Faller, Gilles Fourgaut et al. · American Journal of Respiratory and Critical Care Medicine · 1999 · 575 citations

Medicine, Clinical Sciences, Internal Medicine +11

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rafael Rosell, G. Robinet, A. Szczęsna et al. · Annals of Oncology · 2007 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

Michèle Beau‐Faller, Anne-Marie Ruppert, Anne‐Claire Voegeli et al. · Journal of Thoracic Oncology · 2008 · 199 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol et al. · Annals of Oncology · 2019 · 194 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7